Javascript must be enabled to continue!
HURTHLE CELL NEOPLASM OF THE THYROID GLAND
View through CrossRef
Background: A clinicopathological analysis and long‐term follow up of 32 patients with Hurthle cell neoplasm (HCN) was undertaken to contrast the clinical and histological features between benign versus malignant HCN of thyroid and to examine the effect of treatment on the outcome.Methods: This is a retrospective study of 32 patients with HCN who were identified out of an archival clinical/pathological/imaging database of 3752 thyroid cancer patients seen between 1976 and June 2006. All patients underwent thyroid surgery. Data for the non‐surgical treatment along with follow up were also analysed.Results: Seventeen patients were classified as malignant HCN (MHCN) and 15 as benign HCN (BHCN). Among the MHCN, there were 11 women and 6 men, whereas among BHCN there were 14 women and 1 man. Three patients designated MHCN presented with metastases, one with pulmonary metastases and two others with skeletal metastases who developed lung metastases 9–19 months later. The mean tumour size was 4.43 ± 0.66 cm for MHCN, and 2.57 ± 0.32 cm for BHCN (P = 0.03). Multicentric tumour foci were evident in five cases (29%) of MHCN but none among the BHCN (P = 0.03). At neck exploration cervical lymph node dissection was carried out in nine MHCN patients with findings of tumour metastases in 33%. Postoperatively, three MHCN patients had no thyroid remnant on ultrasound and computed tomography of neck and undetectable serum thyroglobulin; these were considered to be in remission. Fourteen other MHCN patients with postoperative thyroid remnant and/or distant metastases received 131I treatment. Eight of these patients had negative whole‐body scans after 131I treatment and undetectable thyroglobulin. Accordingly, 11 MHCN patients (64.7%) showed evidence of remission and 6 patients did not respond to 131I treatment. After a mean follow up of 35 months, all BHCN patients are alive with no evidence of disease. Of the MHCN, 11 (64.7%) were in remission and 35% had evidence of persistence/recurrence. One patient who had recurrence is dead. A lack of effectiveness of 131I therapy in two patients with distant metastases is an important finding.Conclusion: Features of MHCN consisted of a large tumour size, unequivocal capsular and vascular invasion, multicentric tumour foci, metastatic lymph node deposits in one‐third of patients and presence of distant metastasis in a few. Findings of dominant Hurthle cell cytology in a fine‐needle aspiration biopsy from a thyroid nodule should prompt surgical resection of the lesion to assess malignancy.
Title: HURTHLE CELL NEOPLASM OF THE THYROID GLAND
Description:
Background: A clinicopathological analysis and long‐term follow up of 32 patients with Hurthle cell neoplasm (HCN) was undertaken to contrast the clinical and histological features between benign versus malignant HCN of thyroid and to examine the effect of treatment on the outcome.
Methods: This is a retrospective study of 32 patients with HCN who were identified out of an archival clinical/pathological/imaging database of 3752 thyroid cancer patients seen between 1976 and June 2006.
All patients underwent thyroid surgery.
Data for the non‐surgical treatment along with follow up were also analysed.
Results: Seventeen patients were classified as malignant HCN (MHCN) and 15 as benign HCN (BHCN).
Among the MHCN, there were 11 women and 6 men, whereas among BHCN there were 14 women and 1 man.
Three patients designated MHCN presented with metastases, one with pulmonary metastases and two others with skeletal metastases who developed lung metastases 9–19 months later.
The mean tumour size was 4.
43 ± 0.
66 cm for MHCN, and 2.
57 ± 0.
32 cm for BHCN (P = 0.
03).
Multicentric tumour foci were evident in five cases (29%) of MHCN but none among the BHCN (P = 0.
03).
At neck exploration cervical lymph node dissection was carried out in nine MHCN patients with findings of tumour metastases in 33%.
Postoperatively, three MHCN patients had no thyroid remnant on ultrasound and computed tomography of neck and undetectable serum thyroglobulin; these were considered to be in remission.
Fourteen other MHCN patients with postoperative thyroid remnant and/or distant metastases received 131I treatment.
Eight of these patients had negative whole‐body scans after 131I treatment and undetectable thyroglobulin.
Accordingly, 11 MHCN patients (64.
7%) showed evidence of remission and 6 patients did not respond to 131I treatment.
After a mean follow up of 35 months, all BHCN patients are alive with no evidence of disease.
Of the MHCN, 11 (64.
7%) were in remission and 35% had evidence of persistence/recurrence.
One patient who had recurrence is dead.
A lack of effectiveness of 131I therapy in two patients with distant metastases is an important finding.
Conclusion: Features of MHCN consisted of a large tumour size, unequivocal capsular and vascular invasion, multicentric tumour foci, metastatic lymph node deposits in one‐third of patients and presence of distant metastasis in a few.
Findings of dominant Hurthle cell cytology in a fine‐needle aspiration biopsy from a thyroid nodule should prompt surgical resection of the lesion to assess malignancy.
Related Results
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Abstract
Introduction
Non-Hodgkin lymphoma (NHL) of the thyroid, a rare malignancy linked to autoimmune disorders, is poorly understood in terms of its pathogenesis and treatment o...
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Abstract
Introduction
Due to indeterminate cytology, Bethesda III is the most controversial category within the Bethesda System for Reporting Thyroid Cytopathology. This study exam...
Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine‐needle aspiration?
Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine‐needle aspiration?
AbstractThyroid fine‐needle aspiration (FNA) is a standard procedure for the clinical triage of thyroid nodules. The diagnosis of an adequately sampled thyroid FNA is generally gro...
Recurrence rate in regional lymph nodes in 737 patients with follicular or Hürthle cell neoplasms
Recurrence rate in regional lymph nodes in 737 patients with follicular or Hürthle cell neoplasms
Abstract
Background
Preoperative ultrasound (US) evaluation of central and lateral neck compartments is recommended for all pati...
Carcinoma ex Pleomorphic Adenoma: A Case Series and Literature Review
Carcinoma ex Pleomorphic Adenoma: A Case Series and Literature Review
Abstract
Introduction
Carcinoma ex pleomorphic adenoma (CXPA) is a rare malignant salivary gland tumor that can lead to severe complications and carries a risk of distant metastasi...
SAT567 Collision Tumor Of The Thyroid With Papillary Thyroid Carcinoma And Metastatic Renal Clear Cell Carcinoma With Concomitant Parathyroid Adenoma
SAT567 Collision Tumor Of The Thyroid With Papillary Thyroid Carcinoma And Metastatic Renal Clear Cell Carcinoma With Concomitant Parathyroid Adenoma
Abstract
Disclosure: C.M. Mirano: None. R.C. Mirasol: None.
INTRODUCTION Collision tumors of the thyroid are rare diseases that have two or more histo...
Establishment and preliminary application of personalized three‐dimensional reconstruction of thyroid gland with automatic detection of thyroid nodules based on ultrasound videos
Establishment and preliminary application of personalized three‐dimensional reconstruction of thyroid gland with automatic detection of thyroid nodules based on ultrasound videos
AbstractPurposeA well display of the spatial location of thyroid nodules in the thyroid is important for surgical path planning and surgeon‐patient communication. The aim of this s...
Relationship between serum NDRG3 and papillary thyroid carcinoma
Relationship between serum NDRG3 and papillary thyroid carcinoma
BackgroundIn recent years, papillary thyroid carcinoma is considered to be one of the fastest increaseing cancer. NDRG family member 3 (NDRG3) has been proposed as a molecular mark...

